Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate

Authors


Dr. C. van Drunen, PhD, Head of ENT research, room L3-104-2, Department of Otorhinolaryngology, Academic Medical Center, PO-box 22660, NL-1100 DD Amsterdam, The Netherlands.

Abstract

Mometasone furoate nasal spray (MFNS; Nasonex®, Schering-Plough Corporation, Kenilworth, NJ, USA) is an effective and well-tolerated intranasal corticosteroid approved for the prophylactic treatment of seasonal allergic rhinitis, and the treatment of perennial allergic rhinitis. MFNS is a potent molecule with a rapid onset of action and excellent safety and efficacy profiles. Having recently received approval for the treatment of nasal polyposis, data indicate that MFNS may also be effective in rhinosinusitis.

Ancillary